Utility of [(18)F]FSPG PET to Image Hepatocellular Carcinoma: First Clinical Evaluation in a US Population.
AUTHORS
- NIHMSID: 101125610
ABSTRACT
Non-invasive imaging is central to hepatocellular carcinoma (HCC) diagnosis; however, conventional modalities are limited by smaller tumors and other chronic diseases that are often present in patients with HCC, such as cirrhosis. This pilot study evaluated the feasibility of (4S)-4-(3-[(18)F]fluoropropyl)-L-glutamic acid ([(18)F]FSPG) positron emission tomography (PET)/X-ray computed tomography (CT) to image HCC. [(18)F]FSPG PET/CT was compared to standard-of-care (SOC) magnetic resonance imaging (MRI) and CT, and [(11)C]acetate PET/CT, commonly used in this setting. We report the largest cohort of HCC patients imaged to date with [(18)F]FSPG PET/CT and present the first comparison to [(11)C]acetate PET/CT and SOC imaging. This study represents the first in a US HCC population, which is distinguished by different underlying comorbidities than non-US populations.
Non-invasive imaging is central to hepatocellular carcinoma (HCC) diagnosis; however, conventional modalities are limited by smaller tumors and other chronic diseases that are often present in patients with HCC, such as cirrhosis. This pilot study evaluated the feasibility of (4S)-4-(3-[(18)F]fluoropropyl)-L-glutamic acid ([(18)F]FSPG) positron emission tomography (PET)/X-ray computed tomography (CT) to image HCC. [(18)F]FSPG PET/CT was compared to standard-of-care (SOC) magnetic resonance imaging (MRI) and CT, and [(11)C]acetate PET/CT, commonly used in this setting. We report the largest cohort of HCC patients imaged to date with [(18)F]FSPG PET/CT and present the first comparison to [(11)C]acetate PET/CT and SOC imaging. This study represents the first in a US HCC population, which is distinguished by different underlying comorbidities than non-US populations.
Tags: Faculty Publications 2016